MaxCyte, Inc. (MXCT)
NASDAQ: MXCT · Real-Time Price · USD
1.580
+0.070 (4.64%)
At close: Nov 14, 2025, 4:00 PM EST
1.550
-0.030 (-1.90%)
After-hours: Nov 14, 2025, 7:34 PM EST
MaxCyte Revenue
MaxCyte had revenue of $6.83M in the quarter ending September 30, 2025, a decrease of -16.35%. This brings the company's revenue in the last twelve months to $34.42M, down -24.52% year-over-year. In the year 2024, MaxCyte had annual revenue of $38.63M, down -6.44%.
Revenue (ttm)
$34.42M
Revenue Growth
-24.52%
P/S Ratio
4.87
Revenue / Employee
$301,921
Employees
114
Market Cap
168.54M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 38.63M | -2.66M | -6.44% |
| Dec 31, 2023 | 41.29M | -2.97M | -6.72% |
| Dec 31, 2022 | 44.26M | 10.37M | 30.59% |
| Dec 31, 2021 | 33.89M | 7.73M | 29.52% |
| Dec 31, 2020 | 26.17M | 4.55M | 21.04% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
MXCT News
- 4 days ago - MaxCyte, Inc. (MXCT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - MaxCyte Announces Planned CFO Transition in 2026 - GlobeNewsWire
- 4 days ago - MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance - GlobeNewsWire
- 11 days ago - MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance - GlobeNewsWire
- 5 weeks ago - MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025 - GlobeNewsWire
- 5 weeks ago - MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors - GlobeNewsWire
- 7 weeks ago - MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability - GlobeNewsWire
- 3 months ago - MaxCyte, Inc. (MXCT) Q2 2025 Earnings Call Transcript - Seeking Alpha